New Mexico Joins Growing List of States to Secure Insulin Price Cap Settlements

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • New Mexico AG Raúl Torrez announced settlementswith Sanofi-Aventis U.S. LLC and Novo Nordisk Inc. to resolve allegations that the pharmaceutical companies’ pricing policies resulted in underinsured and uninsured patients paying higher prices for insulin.
  • Under the terms of the agreements, Sanofi-Aventis and Novo Nordisk will cap the price of insulin at $35 per month for uninsured New Mexico residents for the next five years; provide free insulin to the highest-need consumers below the poverty line; clearly disclose insulin affordability programs to consumers; and provide bilingual customer service, among other things.
  • We have previously covered other AGs reaching similar insulin price cap agreements with pharmaceutical companies, including Maine AG Aaron Frey, Minnesota AG Keith Ellison, and New York AG Letitia James.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Cozen O'Connor 2025

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide